Paradigmia
⌕Sign in ↗
Lessons

Embryopathy caused by thalidomide (thalidomide embryopathy).

Created by: Javier Sáez Hurtado

Origin of thalidomide embryopathy

Remember that this lesson is part of the free courses from Paradigmia. Access the full course below 👇👇 PAEDIATRICS COURSE

Thalidomide was given as a sedative and calming agent for hyperemesis gravidarum. It was widely used in the 1960s in northern Europe and, to a lesser extent, in the USA.

The crisis caused by its use in pregnant women is known as “the Thalidomide Catastrophe”, and is an example of the dangers of extrapolating experimental data from animals to humans.

Today this drug is used in oncology, mainly in the treatment of myeloma, because it is anti-angiogenic and therefore very useful for treating cancer. It acts by disruption, so that an organ that was forming stops doing so because its vascularisation is inhibited.

Clinical features of thalidomide embryopathy

  • Amelia: complete absence of one or more limbs.
  • Meromelia or phocomelia: partial absence of one or more limbs.
  • Digestive, ear and cardiac anomalies…
Thalidomide malformation

Since this event, much stricter control has been kept, and the FDA has introduced a risk classification.


Embryopathy caused by anticonvulsant agents

  • Fetal hydantoin syndrome: hypertelorism, hypoplasia of the distal phalanges, heart disease.
  • Fetal barbiturate syndrome.
  • Valproic acid embryopathy.

Studies indicate that the probability of antiepileptic drugs causing an anomaly is 5–6% (slightly higher than in the normal population). However, stopping treatment during pregnancy can lead to poor control of the disease and to status epilepticus (50% fetal mortality). The chances of anomalies in children of untreated epileptic mothers are 2–4%, and in addition, a higher incidence of major malformations in the children of treated epileptic mothers has not been demonstrated. The conclusion is that, with proper monotherapy, the risk of major malformation is no greater than in a child of a non-epileptic mother.

Valproate is not given to women of childbearing age if seizures can be controlled with other drugs. If it is the only drug able to control the seizures, high doses of folic acid must be added during pregnancy to prevent:

  • Neural tube defects.
  • Congenital heart disease.
  • Genital anomalies (hypospadias).
  • Particular facies.
  • IUGR.
  • Limb anomalies.
  • Cognitive disorders of attention, communication and language, as well as autism spectrum disorders.

VPA is avoided in women of childbearing age if their epilepsy can be controlled with other drugs (10% of treated women had newborns affected to a greater or lesser degree). If necessary, folic acid is used at high doses.

Remember that this lesson is part of the free courses from Paradigmia. Access the full course below 👇👇 PAEDIATRICS COURSE

Recommended reading:

Your study

Select a passage in the lesson. Your highlights are private.

0Back to course →
Keep exploring

Knowledge does not end here.

Paradigmia · YouTube ↗